KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- CVS Pharmacists in Rhode Island Petition to Unionize April 18, 2024Nine pharmacists from 2 corporate locations in Wakefield and Westerly are seeking to join the Pharmacy Guild in an attempt to improve working conditions.
- Pharmacies Should Adopt Proactive Health, Wellness to Help Patients April 18, 2024Kathy Campbell, PharmD, discusses why she believes wellness and proactive health are the future of pharmacy and the unique value they offer compared to traditional models.
- How Differences in Bispecific Therapies Impact Myeloma Treatment Operations April 18, 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
- Myeloma Expert: Earlier Use of Bispecifics Can Improve Patient Outcomes April 18, 2024As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.
- Peer Recovery Support May Benefit Patients in Emergency Departments for Opioid Overdose April 18, 2024Patients in ED being treated for an opioid overdose were more likely to initiate medication for opioid use disorder after discharge when they received peer recovery support services.
- Health Care Affordability in the Election Spotlight April 18, 2024More than half of those who responded to a recent KFF survey say they are worried about paying for their prescription drugs.
- Majority of Cancer Drugs with Accelerated FDA Approval Did Not Show Clinical Benefit After 5 Years April 17, 2024Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
- COVID-19 Pandemic Exacerbated Functional Limitations Among Older Adults With Diabetes April 17, 2024Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.
- Congress, CMS Must Take Action to Mitigate Impact of ‘DIR Hangover’ April 17, 2024A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.
- On the Front Lines: Pharmacists' Role in Combating America's Opioid Epidemic April 17, 2024The ongoing opioid crisis in the United States shows no signs of slowing down. As trusted community health care professionals, pharmacists must play a key role in fighting it.
Pharmacy Times articles
- Climate Change Increases Rate of Infectious Diseases, Expert Says April 18, 2024Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.
- Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services April 18, 2024The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein.
- Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years April 18, 2024The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
- Middletown Pharmacy and Wellness Staff Care for the Community April 18, 2024Tara Schneider, PharmD, and her husband, Chuck Schneider, MBA, offer expanded clinical services in their Louisville, Kentucky, pharmacy.
- RSV Vaccine Could Prevent Increased Risk of Disease Among Individuals Aged 18 to 59 April 18, 2024The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety
- Pharmacists Can Improve Access to Pharmacogenomics April 18, 2024Adrijana Kekic, PharmD, a pharmacogenomics clinical specialist with Mayo Clinic in Phoenix, Arizona, discussed current guidelines for pharmacogenomics.
- OTC Contraception Opens New Opportunities for Counseling Patients April 18, 2024With the first FDA-approved option hitting shelves soon, pharmacists can advise patients on the best methods to prevent pregnancy
- Making Residency Research Projects Patient Centered: How Retrospective Research Can Significantly Impact Cancer Care April 18, 2024Through recognizing the importance of research in the scope of pharmacy practice by national pharmacy organizations, research can become a prominent role and responsibility of pharmacy.
- Tirzepatide Demonstrates Reduction in Sleep Apnea-Relate Events April 18, 2024Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.
- Enfortumab Vedotin With Pembrolizumab Shows Promise as First-Line Therapy For Those Ineligible for Cisplatin April 17, 2024Enfortumab vedotin in combination with pembrolizumab showed a manageable safety profile and promising progression free survival and overall survival for locally advanced or metastatic urothelial cancer.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com